Literature DB >> 22580831

Hypertrophic cardiomyopathy: role of current recommendations by the american heart association for infective endocarditis.

Natasha Noel1, Zahra Naheed.   

Abstract

In the past decade, there has been evolution in the diagnosis, management, and long-term care of patients with infective endocarditis and its complications. This includes the relatively new but contentious prophylactic antibiotic regimen. However, these cases still continue to pose a challenge in the adult and pediatric populations. We present a case of a teenager with hypertrophic cardiomyopathy that had an atypical presentation of infective endocarditis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580831     DOI: 10.1007/s00246-012-0324-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  8 in total

1.  Unique features of infective endocarditis in childhood.

Authors:  Patricia Ferrieri; Michael H Gewitz; Michael A Gerber; Jane W Newburger; Adnan S Dajani; Stanford T Shulman; Walter Wilson; Ann F Bolger; Arnold Bayer; Matthew E Levison; Thomas J Pallasch; Tommy W Gage; Kathryn A Taubert
Journal:  Pediatrics       Date:  2002-05       Impact factor: 7.124

2.  In defense of antimicrobial prophylaxis for prevention of infective endocarditis in patients with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Harry Lever
Journal:  J Am Coll Cardiol       Date:  2009-12-08       Impact factor: 24.094

3.  Perspectives on the American College of Cardiology/American Heart Association guidelines for the prevention of infective endocarditis.

Authors:  David S Bach
Journal:  J Am Coll Cardiol       Date:  2009-05-19       Impact factor: 24.094

4.  Musculoskeletal manifestations of bacterial endocarditis.

Authors:  O L Meyers; P J Commerford
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

5.  Musculoskeletal manifestations of bacterial endocarditis.

Authors:  M A Churchill; J E Geraci; G G Hunder
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

6.  Severe mitral or aortic valve regurgitation, or both, requiring valve replacement for infective endocarditis complicating hypertrophic cardiomyopathy.

Authors:  W C Roberts; J C Kishel; C L McIntosh; R O Cannon; B J Maron
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

7.  Viridans streptococcal (Streptococcus intermedius) mitral valve subacute bacterial endocarditis (SBE) in a patient with mitral valve prolapse after a dental procedure: the importance of antibiotic prophylaxis.

Authors:  Burke A Cunha; Alexis A D'Elia; Neha Pawar; Paul Schoch
Journal:  Heart Lung       Date:  2009-07-10       Impact factor: 2.210

8.  Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis.

Authors:  P Spirito; C Rapezzi; P Bellone; S Betocchi; C Autore; M R Conte; G P Bezante; P Bruzzi
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

  8 in total
  1 in total

Review 1.  The pediatric cardiology pharmacopeia: 2013 update.

Authors:  Paul Nicholas Severin; Sawsan Awad; Beth Shields; Joan Hoffman; William Bonney; Edmundo Cortez; Rani Ganesan; Aloka Patel; Steve Barnes; Sean Barnes; Shada Al-Anani; Umang Gupta; Yolandee Bell Cheddar; Ismael E Gonzalez; Kiran Mallula; Hani Ghawi; Suhaib Kazmouz; Salwa Gendi; Ra-id Abdulla
Journal:  Pediatr Cardiol       Date:  2012-11-29       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.